Contrast Induced Nephropathy Clinical Trial
Official title:
Aging Biomakers and ConTrast Induced Nephropathy (ACTIN) Trial
Biomarkers such as kidney injury molecule-1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) have been used for the early diagnosis of AKI, although with no definitive results. The investigators explored the association between plasma aging biomakers such as sklotho and contrast induced nephropathy in patients undergoing percutaneous coronary intervention (PCI) with contrast injection.
Acute kidney injury represents an important clinical problem in hospitalized patients, with
persistently high rates of mortality and morbidity. With an ever-increasing number of
patients receiving intravascular injection of iodinated contrast media worldwide, contrast
induced nephropathy (CIN) has become the third leading cause of hospital-acquired AKI.
Approximately half of these cases are in patients undergoing cardiac catheterization
procedures.
The prevention and early intervention of CIN has been hampered mainly by the lack of a
consensus definition and the paucity of early predictive biomarkers to accurately identify
high-risk patients. CIN is most frequently defined as an increase in serum creatinine (sCr)
by 25-50% above the baseline, generally occurring within the first 24 h after contrast
exposure, in the absence of other causes. However, sCr is an unreliable indicator during
acute changes in kidney function, and alterations in sCr levels are not particularly
sensitive or specific for small changes in the glomerular filtration rate (GFR)e, gender,
race and intravascular volume. Biomarkers such as kidney injury molecule-1 (KIM-1) and
neutrophil gelatinase-associated lipocalin (NGAL) have been used for the early diagnosis of
AKI, although with no definitive results.
;
Observational Model: Case Control, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00842868 -
The CASABLANCA Study: Catheter Sampled Blood Archive in Cardiovascular Diseases
|
N/A | |
| Completed |
NCT00634491 -
Comparison Between Effect of Acetazolamide and NaHco3 in Prevention of Contrast Nephropathy
|
Phase 2 | |
| Terminated |
NCT00476619 -
Erythropoietin in Radiocontrast Induced Nephropathy (ERIN) Trial
|
Phase 4 | |
| Recruiting |
NCT03121053 -
Preventing contrAst Induced Nephropathy After TranscathEter Aortic Valve Replacement
|
Phase 4 | |
| Completed |
NCT01741896 -
Can Remote Ischaemic Preconditioning Reduce Contrast Induced Nephropathy in Patients Receiving Contrast for Computed Tomography?
|
N/A | |
| Terminated |
NCT00575419 -
Safety Study Of N-Acetylcysteine For Prevention Of Contrast Induced Nephropathy In Patients w/Stage 3 Renal Failure
|
Phase 1 | |
| Not yet recruiting |
NCT00392405 -
Prevention of Contrast Induced Nephropathy With Sodium Bicarbonate
|
Phase 2 | |
| Completed |
NCT00292487 -
Patients With Renal Impairment Undergoing CT
|
Phase 4 | |
| Recruiting |
NCT04982419 -
Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial
|
Phase 2/Phase 3 | |
| Completed |
NCT00770614 -
Hydration and Contrast-Induced Nephropathy in Primary Angioplasty
|
Phase 4 | |
| Completed |
NCT01999517 -
Contrast Nephropathy and Nitrates
|
Phase 4 | |
| Recruiting |
NCT00702728 -
Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy (CIN) Prevention
|
Phase 3 | |
| Completed |
NCT00531765 -
Sodium Bicarbonate in Preventing Contrast Induced Nephropathy
|
N/A | |
| Completed |
NCT00639912 -
Effects of Hydration to Prevent Contrast Induced Nephropathy in PCI for ST-elevation Myocardial Infarction.
|
Phase 4 | |
| Terminated |
NCT00494637 -
The Use of Sodium Bicarbonate in the Prevention of Contrast Induced Nephropathy
|
N/A | |
| Completed |
NCT02516072 -
Use of Remote Ischaemic Preconditioning in the Prevention of Contrast Induced Nephropathy
|
N/A | |
| Active, not recruiting |
NCT01402232 -
REduction of rIsk for Contrast Induced Nephropathy
|
||
| Recruiting |
NCT02113540 -
Assessment of the Effect of Atorvastatin on Prevention of CIN in Patients Undergoing Coronary Angiography
|
Phase 3 | |
| Active, not recruiting |
NCT01456013 -
Evaluation of RenalGuard® System to Reduce the Incidence of Contrast Induced Nephropathy in At-Risk Patients
|
Phase 3 | |
| Recruiting |
NCT01399203 -
Contrast Medium Volume and Contrast-induced Nephropathy After Percutaneous Coronary Intervention
|
N/A |